Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple neck injection ease fibromyalgia pain?

NCT ID NCT07343128

Symptom relief Sponsor: Sanliurfa Education and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an ultrasound-guided nerve block injection (stellate ganglion block) could help people with fibromyalgia who still have symptoms despite taking duloxetine. 68 adults received either the active injection or a sham (fake) injection, and researchers measured changes in pain and overall impact after one week and one month. The goal was to see if this procedure offers a safe and effective add-on treatment for hard-to-treat fibromyalgia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine and dexamethasone injection
What this could lead to
If it works, this could provide a new way to reduce pain and improve daily life for people with fibromyalgia who don't get enough relief from standard medications.
What could go wrong
This is a small, early-phase study with only 68 participants. The results may not apply to everyone, and the benefits might be short-lived or no better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

68 people

The number who actually took part.

Started

Jun 2025

Finished

Dec 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Fibromyalgia Syndrome (FMS) according to the 2016 American College of Rheumatology criteria. * Followed for at least 1 year with insufficient benefit from previous pharmacological and/or non-pharmacological treatments. * Receiving a stable dose of duloxetine 60 mg once daily for at least 4 weeks prior to inclusion. * Willingness to continue the fixed dose of duloxetine throughout the study. * Aged between 18 and 65 years. Exclusion Criteria: * Non-pharmacological treatments within the previous 6 months (e.g., acupuncture, ozone therapy, cognitive behavioral therapy). * Local infection at the injection site. * Pregnancy or suspected pregnancy. * Known allergy to local anesthetics. * History of malignancy. * Bleeding or coagulation disorders or use of oral anticoagulants. * Uncontrolled hypertension, diabetes mellitus, asthma, chronic obstructive pulmonary disease, or heart failure. * Psychiatric or cognitive disorders that could interfere with treatment compliance (e.g., severe psychiatric illness, dementia). * Refusal of interventional treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibromyalgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fibromyalgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibromyalgia

Contacts and locations

Locations

  • Sanliurfa Education and Research Hospital

    Sanliurfa, Şanlıurfa, 63290, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.